Potential of hypoglycemic therapy to reduce the risk of recurrent cardiovascular events in individuals without diabetes mellitus
Abstract. Cardiovascular diseases (CVD) remains one of the leading causes of death and disability worldwide. The risk of CVD recurrence remains high despite secondary prevention measures. Modern glucose-lowering medications demonstrate high efficacy in reducing the risk of CVD. The research of hypoglycemic therapy in the past decade has been devoted to people without diabetes if they suffer from chronic heart failure or chronic kidney disease. This article includes the results of the main clinical trials of cardioprotective hypoglycemic drugs: pioglitazone, sodium-glucose transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in relation to their effect on cardiovascular mortality, myocardial infarction, and ischemic stroke. The data presented indicate significant potential for this therapy in the comprehensive secondary prevention of cardiovascular disease in patients both with type 2 diabetes and without diabetes.E.A. Shestakova, E.V. Vechorko
Keywords
cardiovascular disease
myocardial infarction
ischemic stroke
hypoglycemic agents
secondary prevention
References
- Федеральная служба государственной статистики (Росстат). Здравоохранение в России. 2025. Статистический сборник. М.: Росстат. 2025; 149 с. Доступ: https://www.rosstat.gov.ru/storage/mediabank/Zdravooxran_2025.pdf (дата обращения – 14.06.2026). [Federal State Statistics Service (Rosstat). Healthcare in Russia. 2025. Statistical compendium. Moscow: Rosstat. 2025; 149 pp. URL: https://www.rosstat.gov.ru/storage/mediabank/Zdravooxran_2025.pdf (date of access – 14.06.2026) (In Russ.)].
- Дедов И.И., Шестакова М.В., Мокрышева Н.Г., Викулова О.К., Железнякова А.В., Шамхалова М.Ш. с соавт. Клинико-эпидемиологический анализ показателей сахарного диабета в Российской Федерации, статус 01.01.2026 г. Сахарный диабет. 2026;29(2):104–136. [Dedov II, Shestakova MV, Mokrysheva NG, Vikulova OK, Zheleznyakova AV, Shamkhalova MS et al. Clinical and epidemiological analysis of diabetes mellitus indicators in the Russian Federation, updated January 1, 2026. Sakharnyy diabet = Diabetes Mellitus. 2026;29(2):104–136 (In Russ.)].
EDN: PNTHWO. https://doi.org/10.14341/DM13485
- Li FR, Yang HL, Zhou R, Zheng JZ, Chen GC, Zou MC, et al. Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality. Diabetes Obes Metab. 2021;23(6):1361–70.
PMID: 33620747. https://doi.org/10.1111/dom.14348
- Дедов И.И., Шестакова М.В., Сухарева О.Ю., Мокрышева Н.Г., Андреева Е.Н., Безлепкина О.Б. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, О.Ю. Сухаревой. 12-й выпуск. Сахарный диабет. 2025;28(5S):1–175. [Dedov II, Shestakova MV, Sukhareva OYu, Mokrysheva NG, Andreeva EN, Bezlepkina OB, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Sukhareva OYu. 12th edition. Sakharnyy diabet = Diabetes Mellitus. 2025;28(5S):1–175 (In Russ.)].
https://doi.org/10.14341/DM20255S
- Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.
PMID: 16214598. https://doi.org/10.1016/S0140-6736(05)67528-9
- Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772–80.
PMID: 17466227. https://doi.org/10.1016/j.jacc.2006.12.048
- Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38(3):865–73.
PMID: 17290029. https://doi.org/10.1161/01.STR.0000257974.06317.49
- Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321–31.
PMID: 26886418. PMCID: PMC4887756. https://doi.org/10.1056/NEJMoa1506930
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
PMID: 26378978. https://doi.org/10.1056/NEJMoa1504720
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
PMID: 28605608. https://doi.org/10.1056/NEJMoa1611925
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.
PMID: 30415602. https://doi.org/10.1056/NEJMoa1812389
- McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
PMID: 31535829. https://doi.org/10.1056/NEJMoa1911303
- Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.
PMID: 32865377. https://doi.org/10.1056/NEJMoa2022190
- Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.
PMID: 32970396. https://doi.org/10.1056/NEJMoa2024816
- The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27.
PMID: 36331190. PMCID: PMC7614055. https://doi.org/10.1056/NEJMoa2204233
- Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.
PMID: 36027570. https://doi.org/10.1056/NEJMoa2206286
- Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.
PMID: 34449189. https://doi.org/10.1056/NEJMoa2107038
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
PMID: 27295427. PMCID: PMC4985288. doi: 10.1056/NEJMoa1603827
- Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
PMID: 27633186. https://doi.org/10.1056/NEJMoa1607141
- Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
PMID: 31189511. https://doi.org/10.1016/S0140-6736(19)31149-3
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.
PMID: 37952131. https://doi.org/10.1056/NEJMoa2307563
- Lam CSP, Rodriguez A, Aminian A, Ferrannini E, Heerspink HJL, Jastreboff AM, et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: Rationale and design of the SURMOUNT-MMO trial. Obesity (Silver Spring). 2025;33(9):1645–56.
PMID: 40545827. https://doi.org/10.1002/oby.24332
About the Authors
Ekaterina A. Shestakova, MD, Dr. Sci. (Medicine), professor of the Department of endocrinology, Russian Medical Academy of Continuous Professional Education; chief researcher at Endocrinology Research Centre, Moscow, Russian Federation.E-mail: katiashestakova@mail.ru
ORCID: https://orcid.org/0000-0001-6612-6851. eLibrary SPIN: 1124-7600
Ekaterina V. Vechorko, MD, resident of Endocrinology Research Centre, Moscow, Russian Federation.
ORCID: https://orcid.org/0009-0004-4012-4638
Similar Articles
